Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma’s Concord, ON facility will become Rubicon’s Nasal and Pulmonary Center of Excellence.
Impopharma’s services included testing and development of nasal sprays, MDIs, and DPIs. According to Rubicon, the company expects the new center of excellence to continue to take on external OINDP development projects as well as internal projects.
Rubicon CEO Parag Sancheti said, “I welcome the Impopharma team to the Rubicon Research family and look forward to building new projects and capabilities together.”
Read the Rubicon Research press release.
